Office blood pressure (OBP) was measured with a mercury sphygmomanometer every 2 weeks during the placebo period and at weeks 2, 4, 8, 12, 16 and 20 of the treatment period. Ambulatory BP monitoring was carried out 2 weeks after starting placebo and 8 and 16 weeks after starting drug treatment.